will submit a copy to the Office of Management and Budget for its review.

Public reporting burden for this collection of information is estimated to average 2 minutes per response. This includes the time it will take to read the instructions, gather the necessary facts, and provide the information. If you have any comments or suggestions on this estimate, write to the Social Security Administration, ATTN: Reports Clearance Officer, 1–A–21 Operations Building, Baltimore, MD 21235.

(Catalog of Federal Domestic Assistance Program Nos. 96.001 Social Security—Disability Insurance; 96.002 Social Security—Retirement Insurance; 96.004 Social Security—Survivors Insurance; 96.006 Supplemental Security Income)

List of Subjects in 20 CFR Part 422

Administrative practice and procedure; Freedom of information; Organization and functions (Government agencies); Social Security.

Dated: June 14, 1995.

Shirley S. Chater,

Commissioner of Social Security.

For the reasons set out in the preamble, Subpart B of Part 422 of 20 CFR Chapter III is amended as follows:

PART 422—ORGANIZATION AND PROCEDURES

1. The authority citation for Subpart B is revised to read as follows:

Authority: Secs. 205, 702, and 1143 of the Social Security Act; 42 U.S.C. 405, 902, and 1320b–13.

2. Section 422.107 is amended by adding language at the end of paragraph (c), to read as follows:

§ 422.107 Evidence requirements.

(c) *Evidence of identity.* * * * An applicant for a duplicate social security number card who is a U.S. citizen and who resides in an area where the Social Security Administration is conducting a pilot project on the issuance of duplicate cards will not be required to submit a signed application or corroborative documentary evidence of identity if the Social Security Administration is able to compare information provided by the applicant with information already in its records and, on the basis of this comparison, decides that corroborative documentary evidence is not needed to establish the applicant's identity. These special procedures do not apply to foreign-born U.S. citizens who have not already submitted evidence of citizenship to us; to a person applying on behalf of another if the applicant is not a parent applying on behalf of his or her minor child; and to people whose address is an in-care-of address, a post office box, general delivery, or a suite.

* * * * *

[FR Doc. 95–15301 Filed 6–21–95; 8:45 am]

BILLING CODE 4190–29–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 510

New Animal Drugs; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for 46 new animal drug applications (NADA's) from Sanofi Animal Health, Inc., to Rhone Merieux, Inc.

EFFECTIVE DATE: June 22, 1995.

FOR FURTHER INFORMATION CONTACT: Judith M. O'Haro, Center for Veterinary Medicine (HFV–238), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1737.

SUPPLEMENTARY INFORMATION: Sanofi Animal Health, Inc., 7101 College Blvd., Overland Park, KS 66210, has informed FDA that it has transferred ownership of, and all rights and interests in, the following approved NADA's to Rhone Merieux, Inc., 7101 College Blvd., Overland Park, KS 66210:

NADA number	Drug name
006–623	Caparsolate
008–422	Seleen Suspension
010–092	Gallimycin'-50P Premix
010–346	Combuthal Powder
012–123	Gallimycin-100, Gallimycin LA Injectable, Erythro-200 Injection
033–157	Spectam Scour Halt
035–157	Gallimycin Poultry Formula
035–455	Gallimycin-36/Dry
035–456	Gallimycin 36 Sterile
038–241	Erythro +ZOA+ARS Acid
038–242	Erythro +AMP+ETHO
038–624	Pro-Gallimycin-10
038–661	Spectam Water Soluble Concentrate
040–040	Spectam Injection
041–955	Erythromycin Premix
044–756	Butatron Tablets
045–416	Butatron Injection
048–287	Oxytetracycline-50 Injection
055–002	Chloramphenicol Injection
055–059	Viceton Tablets
065–275	Penicillin VK Filmtab
065–276	Veesyn Granules for Oral Solution
065–383	Procaine G Penicillin Mastitis Tubes
065–384	Procaine G Penicillin Mastitis Tubes
093–483	Spectam Injectable
093–515	Spectam Tablets
095–218	Dexamethasone Tablets
097–397	Syncro-Mate-B
098–379	Cystorelin Injectable
100–128	Medipak Tylan 10
101–690	Erythro-100 Injectable
102–656	Gallimycin Poultry Formula
107–506	Carbam Tablets & Film Coated Tablets
113–510	Equipalazone
118–032	Carbam Palatabs
118–979	Butatron Oral Gel
119–142	Injectable Iron 10%
120–615	Sustain III Calf & Cattle Bolus
123–815	Dexarnethasone Sodium Phosphate Injection
124–241	Oxytocin Injection
126–504	Nitrozone Ointment
128–089	Dexamethasone Sterile Solution
134–930	Syncro-Mate-B
200–050	Neomycin 325 Soluble Powder
200–103	Penicillin G Potassium
200–147	Gentamicin Sulfate Injection

Accordingly, FDA is amending the regulations in 21 CFR 510.600(c)(1) and (c)(2) to reflect the change of sponsor. The drug labeler code assigned to Sanofi Animal Health, Inc., is being retained as the drug labeler code for Rhone Merieux, Inc.

List of Subjects in 21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: Secs. 201, 301, 501, 502, 503, 512, 701, 721 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e).